CRSP — Crispr Therapeutics AG Balance Sheet
0.000.00%
- $5.42bn
- $3.50bn
- $37.31m
- 40
- 14
- 90
- 45
Annual balance sheet for Crispr Therapeutics AG, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,690 | 2,379 | 1,815 | 1,694 | 1,904 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.144 | 0.305 | 0 | 200 | 25 |
| Prepaid Expenses | |||||
| Total Current Assets | 1,717 | 2,418 | 1,853 | 1,908 | 1,937 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 93 | 312 | 321 | 306 | 278 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,828 | 2,752 | 2,243 | 2,230 | 2,242 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 94.3 | 120 | 121 | 109 | 87.8 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 164 | 352 | 368 | 347 | 310 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 1,664 | 2,399 | 1,875 | 1,883 | 1,932 |
| Total Liabilities & Shareholders' Equity | 1,828 | 2,752 | 2,243 | 2,230 | 2,242 |
| Total Common Shares Outstanding |